Boston Scientific Corp Stock (BSX) Closed Down by 5.56% on Apr 24: Drivers Behind the Movement

Boston Scientific Corp (BSX) closed down by 5.56%. The Healthcare Services & Equipment sector is down by 0.39%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) up 0.12%; HCA Healthcare Inc (HCA) down 8.63%; Intuitive Surgical Inc (ISRG) up 0.73%.

What is driving Boston Scientific Corp (BSX)’s stock price down today?

Boston Scientific (BSX) experienced a notable intraday stock decline, primarily driven by a downward revision of its full-year 2026 guidance, despite reporting better-than-expected first-quarter results. The company’s Q1 2026 revenue of $5.2 billion and adjusted earnings per share (EPS) of $0.80 surpassed analyst estimates of $5.17 billion and $0.79, respectively. However, the positive Q1 performance was overshadowed by the updated outlook.

Management reduced its full-year 2026 adjusted profit forecast to a range of $3.34 to $3.41 per share, down from the previous projection of $3.43 to $3.49 per share. This revised outlook falls below the average analyst expectation of $3.45 per share. Additionally, the company trimmed its full-year organic revenue growth forecast to 6.5% to 8%, a decrease from the prior range of 10% to 11%. This guidance cut was attributed to unanticipated headwinds in several key segments, including WATCHMAN, U.S. Electrophysiology (EP), and Urology, as well as broader macro uncertainty and tariffs.

Concerns surrounding the sustainability of growth in the U.S. EP segment and softness in WATCHMAN volumes, which softened from mid-February, contributed to investor apprehension. Despite the positive clinical trial data for products like WATCHMAN FLX and FARAPULSE, and strategic acquisitions such as Valencia Technologies and the planned Penumbra deal, the lowered guidance led several analyst firms to trim their price targets for BSX, although many maintained bullish ratings, viewing the pullback as a "reset opportunity."

Adding to the complexity, a class-action lawsuit was filed, alleging that Boston Scientific made misleading statements concerning the growth rate of its U.S. EP segment, and that management was aware of an unsustainable growth rate. This legal development, combined with previous reports of pacemaker battery issues and associated recalls, could contribute to negative market sentiment and increased scrutiny on the company.

Technical Analysis of Boston Scientific Corp (BSX)

Technically, Boston Scientific Corp (BSX) shows a MACD (12,26,9) value of [-2.42], indicating a neutral signal. The RSI at 50.49 suggests neutral condition and the Williams %R at -15.88 suggests oversold condition. Please monitor closely.

Fundamental Analysis of Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $20.07B, ranking 11 in the industry. The net profit is $2.90B, ranking 6 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $88.53, a high of $118.00, and a low of $69.00.

More details about Boston Scientific Corp (BSX)

Company Specific Risks:

• Boston Scientific faces financial headwinds due to reduced 2026 organic growth guidance and a lowered full-year adjusted EPS forecast, driven by slower-than-anticipated trends in its U.S. electrophysiology and Watchman device segments, as well as new issues in urology and cardiac rhythm management.
• Multiple class action lawsuits allege that Boston Scientific made false and misleading statements or concealed material adverse facts regarding the unsustainable growth rate and competitive landscape of its U.S. Electrophysiology segment, leading to significant stock price declines following Q4 2025 financial results and underwhelming guidance.
• The proposed $14.9 billion acquisition of Penumbra is encountering regulatory scrutiny, including an FTC second request that has delayed its progression, and carries a notable regulatory termination fee, while also being projected to be dilutive to adjusted earnings per share in the first full year.